Description

1. Product Overview: Lenvaxen 10 is a targeted anticancer agent containing Lenvatinib INN 10 mg, used for the treatment of various types of thyroid, renal, and hepatocellular carcinomas.
2. Composition: Active Ingredient: Lenvatinib INN 10 mg | Dosage Form: Capsule
3. Pharmacological Class: Receptor Tyrosine Kinase (RTK) Inhibitor
4. Mechanism of Action: Lenvatinib inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors and other RTKs that are implicated in pathogenic angiogenesis, tumor growth, and cancer progression.
5. Indications: Differentiated Thyroid Cancer (DTC) | Renal Cell Carcinoma (RCC) | Hepatocellular Carcinoma (HCC) | Endometrial Carcinoma
6. Dosage & Administration: As prescribed by oncologist | Oral use | Take once daily at the same time | May be taken with or without food | Swallow capsules whole
7. Clinical Benefits: Inhibits tumor angiogenesis | Delays disease progression | Targeted therapeutic approach | Effective in multiple cancer types
8. Contraindications: Hypersensitivity to Lenvatinib or any component
9. Precautions: Monitor blood pressure regularly | Monitor for proteinuria and renal function | Risk of cardiac dysfunction and hepatotoxicity | Monitor for gastrointestinal perforation
10. Drug Interactions: No significant interactions with CYP3A4 inhibitors/inducers, but monitor closely with other QT-prolonging drugs
11. Special Populations: Pregnancy contraindicated due to fetal harm | Lactation not recommended | Dose adjustment required for severe renal or hepatic impairment
12. Adverse Effects: Hypertension | Fatigue | Diarrhea | Decreased appetite | Weight loss | Palmar-plantar erythrodysesthesia (hand-foot syndrome)
13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children
14. Packaging: Capsule in blister pack
15. Manufacturer: Everest Pharmaceutical Ltd.